Pharmacology and clinical experience with alosetron

Bibliography

• DROSSMANDA, LI Z andRUZZI E et al: US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig. Dis. Sci. (1993) 38:1569–1580.
   PubMed Web of Science ®Google Scholar
• ••Major epidemiological survey documenting the prevalenceand impact of functional gastrointestinal disorders.
   Google Scholar
• TALLEY NJ, ZINSMEISTER AR, VAN DYKE C, MELTON LJ III: Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology (1991) 101:927–934.
   PubMed Web of Science ®Google Scholar
• SWITZ DM: What the gastroenterologist does all day. Asurvey of a state society's practice. Gastroenterology (1976) 70:1048–1050.
   Google Scholar
• CAMILLERI M, CHOI M-G: Review article: irritable bowel syndrome. Aliment. Pharm. Ther. (1997) 11:3–15.
   Google Scholar
• ••Review of the state of knowledge regarding global epidemi-ology, mechanisms, investigation and management of IBS including summary of efficacy of antispasmodic agents.
   Google Scholar
• GWEE KA, GRAHAM JC, MCKENDRICK MW eta].: Psycho-metric scores and persistence of irritable bowel after infectious diarrhoea. Lancet (1996) 347:150–153.
   Google Scholar
• CAMILLERI M, PRATHER CM: The irritable bowelsyndrome: mechanisms and a practical approach to management. Ann. Intern. Med. (1992) 116:1001–1008.
   PubMed Web of Science ®Google Scholar
• DROSSMAN DA, WHITEHEAD WE, CAMILELRI M: Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology (1997) 112:2120–2137.
   PubMed Web of Science ®Google Scholar
• ••Authoritative, comprehensive review of the mechanisms,psychosocial disorders and management of IBS with detailed evaluation of the effects of psychopharmacological agents.
   Google Scholar
• CUBEDDU LX: Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology (1996) 53:18–25.
   PubMed Web of Science ®Google Scholar
• GERSHON MD: Serotonin: its role and receptors inenteric neurotransmission. Adv. Exp. Med. Biol. (1991) 294:221–230.
   PubMedGoogle Scholar
• GERSHON MD: Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment. Pharm. Ther. (1999) 13:15–30.
   PubMed Web of Science ®Google Scholar
• VON DER OHE MR, CAMILLERI M, KVOLS LK: A 5-11T3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroen-terology (1994) 106:1184–1189.
   PubMed Web of Science ®Google Scholar
• VON DER OHE MR, HANSON RB, CAMILLERI M: Seroto-nergic mediation of postprandial colonic tonic and phasic responses in humans. Gut (1994) 35:536–541.
   PubMed Web of Science ®Google Scholar
• ••Clinical pharmacology study providing rationale for the useof serotonergic type 3 antagonists in IBS.
   Google Scholar
• VON DER OHE MR, CAMILLERI M, KVOLS LK, THOMFORDE GM: Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N. EngL J. Med. (1993) 329:1073–1078.
   PubMed Web of Science ®Google Scholar
• ••Disease model illustrating the manifestations of excessiveproduction and circulation of serotonin and the mechanism of carcinoid diarrhoea.
   Google Scholar
• SASLOW SB, SCOLAPIO JS, CAMILLERI M et al.: Medium- term effects of a new 51IT3 antagonist, alosetron, in patients with carcinoid diarrhoea. Gut (1998) 42:628–634.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of the beneficial effects of alosetron in thecontext of a hyperserotonaemic disorder.
   Google Scholar
• DELVAUX M, LOUVEL D, MAMET JP, CAMPOS-ORIOLA R, FREXINOS J: Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment. Pharm. Ther. (1998) 12:849–855.
   PubMed Web of Science ®Google Scholar
• •Demonstration of the effects of alosetron on colonic compli-ance and sensation in IBS.
   Google Scholar
• PRIOR A, READ NW: Reduction of rectal sensitivity and postprandial motility by granisetron, a 5HT3 receptor antagonist, in patients with irritable bowel syndrome. Aliment. Pharm. Ther. (1993) 7:175–180.
   PubMed Web of Science ®Google Scholar
• THUMSHIRN M, COULIE B, CAMILLERI M, BURTON D, ZINSMEISTER AR: Evaluation of potential sites of action of alosetron in irritable bowel syndrome. Neurogastro-enterol. Motility (1999) 11:295 (Abstract).
   Google Scholar
• Clinical Investigators' Brochure: Alosetron (GR68755). Glaxo Wellcome Research and Development, Greenford, Middlesex, UK (July 1995).
   Google Scholar
• HOUGHTON LA, FOSTER J, WHORWELL PJ, MCDONALD JN: Effect of alosetron, a new 5HT3 antagonist, on gastrointestinal transit in normal healthy volunteers. Gastroenterology (1995) 108:A618. (Abstract).
   Google Scholar
• ZERBIB F, BRULEY DES VARANNES S, ORIOLA RC, MCDONALD J, ISAL JP, GALMICHE JP: Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment. Pharm. Ther. (1994) 8:403–407.
   PubMed Web of Science ®Google Scholar
• FOSTER JM, HOUGHTON LA WHORWELL PJ: Alosetron slows colonic transit in patients with irriTable bowel syndrome. Gastroenterology (1997) 112:A732 (Abstract).
   Google Scholar
• BEARCROFT CP andRE EA FARTHING MJ: In vivo effects of the 51IT3 antagonist, alosetron, on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study. Aliment. Pharm. Ther. (1997) 11:1109–1114.
   PubMed Web of Science ®Google Scholar
• CAMILLERI M, MAYER EA, DROSSMAN DA et al: Improve- ment in pain and bowel function in female irritable bowel patients with alosetron, a 511T3-receptor antagonist. Aliment. Pharm. Ther. (1999) 13:610–620.
   Google Scholar
• ••Phase IIb trial demonstrating the efficacy of alosetron infemales with IBS and optimal dosage for safety and efficacy.
   Google Scholar
• BARDHAN K, BODEMAR G, GELDOF H, SCHUTZ E, SNELL C, DAREKAR B: A double-blind, placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Gastroenter-ology (1996) 110:A630. (Abstract).
   Google Scholar
• CAMILLERI M, NORTHCUTT AR, KONG S, DUKES GE, MCSORLEY D, MANGEL AW: The efficacy and safety of alosetron in female patients with irritable bowel syndrome: a randomised, placebo controlled trial. Lancet (Submitted).
   Google Scholar
• CAMILLERI M, CHEY WY, MAYER EA et al.: Alosetron relieves abdominal pain and improves abnormal bowel function in female, non-constipated irritable bowel syndrome patients. Gastroenterology (Submitted).
   Google Scholar
• JONES RH, HOLTMANN G, RODRIGO L et al: Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment. Pharm. Ther. (1999) 13 :1419–1427.
   PubMed Web of Science ®Google Scholar